Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement
|Videos|July 11, 2018

Evolving Treatment Landscape of Renal Cell Carcinoma

Advertisement

Episodes in this series

EP. 1 Newly Diagnosed Metastatic Renal Cell Carcinoma
EP. 1 Newly Diagnosed Metastatic Renal Cell Carcinoma
EP. 2 mRCC Patient Selection for Ipilimumab/Nivolumab
EP. 2 mRCC Patient Selection for Ipilimumab/Nivolumab
EP. 3 mRCC: Cytoreductive Nephrectomy in the Modern Era
EP. 3 mRCC: Cytoreductive Nephrectomy in the Modern Era
EP. 4 Risk Stratification for Metastatic Renal Cell Carcinoma
EP. 4 Risk Stratification for Metastatic Renal Cell Carcinoma
EP. 5 Selecting Immunotherapy versus VEGF TKI for mRCC
EP. 5 Selecting Immunotherapy versus VEGF TKI for mRCC
EP. 6 Deferred Therapy for Favorable-Risk mRCC Patients
EP. 6 Deferred Therapy for Favorable-Risk mRCC Patients
EP. 7 VEGF TKI + Immunotherapy Combinations for mRCC
EP. 7 VEGF TKI + Immunotherapy Combinations for mRCC
EP. 8 Sunitinib 4/2 vs 2/1 Schedule for Patients with mRCC
EP. 8 Sunitinib 4/2 vs 2/1 Schedule for Patients with mRCC
EP. 9 Disease Progression in Patients with Metastatic RCC
EP. 9 Disease Progression in Patients with Metastatic RCC
EP. 10 Sequencing Approaches in Metastatic Renal Cell Carcinoma
EP. 10 Sequencing Approaches in Metastatic Renal Cell Carcinoma
EP. 11 Considerations for Using Adjuvant Therapy in mRCC
EP. 11 Considerations for Using Adjuvant Therapy in mRCC
EP. 12 Evolving Treatment Landscape of Renal Cell Carcinoma
Now Playing
EP. 12 Evolving Treatment Landscape of Renal Cell Carcinoma

Transcript:

Advertisement
Genitourinary Cancers
|
Evolving Treatment Paradigms for Renal Cell Carcinoma

Related to this article

View more
RCC | Image Credit: © Ashling Wahner & MJH Life Sciences Using AI
July 15th, 2026
Adjuvant Penpulimab Improves DFS in Very High-Risk Clear Cell RCC
Phase 2 data show adjuvant penpulimab significantly improves disease-free survival vs surveillance in very high-risk clear cell renal cell carcinoma.
Read more
Advertisement
Advertisement

Trending on OncLive

1

FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC

2

PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings

3

META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL

4

CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML

5

Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us